MedTrace Logo

Evaluating Efficacy and Safety of Oral Melatonin in Acute Central Serous Chorioretinopathy

NCT06809751 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-02-05

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if oral melatonin can enhance visual acuity and central macular thickness in central serous chorioretinopathy (CSCR) in adults. The main questions it aims to answer are:

1. How does melatonin affect central macula thickness in CSCR?
2. How does melatonin affect visual acuity in CSCR? Researchers will compare placebo (a look-like substance that contains no drug) to see if melatonin works to treat CSCR.

Participants will:

1. Take melatonin or placebo twice a day for one month
2. Visit the clinic after finishing a course of treatment, and 1 and 3 months after that for visual acuity assessment and tests
3. Keep a diary of their symptoms

Conditions

  • Central Serous Chorioretinopathy
  • Melatonin
  • Ocular Diseases
  • Visual Acuity
  • Macula Abnormality

Interventions

DRUG

melatonin 3mg

In this group, participants will be randomly assigned to take 3 mg tablets of melatonin twice a day for 1 month.

DRUG

Placebo Drug

The placebo is also prepared in the form of tablets with similar packaging as melatonin by the pharmaceutical company. Participants will be randomly assigned to take placebo with the same frequency and duration as melatonin (twice a day for 1 month).

Sponsors & Collaborators

  • Mohsen Pourazizi

    lead OTHER

Principal Investigators

  • Mohsen Pourazizi · Isfahan University of Medical Sciences, Feiz Hospital, Isfahan Isfahan, Isfahan, Iran

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2025-05-01
Completion
2025-06-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06809751 on ClinicalTrials.gov